Estimation of plasmic concentration of the brain natriuretic peptide in interstitial pulmonary diseases with pulmonary hypertension: clinical role


Aim. To study a plasmic concentration of the brain natriuretic peptide (BNUP) in patients with interstitial pulmonary disease (IPD) as a possible diagnostic parameter in pulmonary hypertension (PH).
Material and methods. Plasmic BNUP concentration, external respiration function were studied in 24 patients with IPD. The following tests were also made: 6-min walk, echocardiography (echo-CG) with estimation of systolic pressure in the pulmonary artery, multislice computed tomography of the chest with measurement of the mean diameter of the pulmonary artery trunk.
Results. As shown by echo-CG and chest MSCT half of the IPD patients had PH. IPD patients with PH had a significant elevation of plasmic BNUP concentration which, in intact left ventricular contractile function indicates development of secondary PH characterized by reduction of volume parameters of the respiratory pulmonary function. The rise of BNUP concentration correlated with reduction of 6-min walk distance and functional lung capacity.
Conclusion. Plasmic BNUP can be used for diagnosis of PH in IPD patients.


  1. Мухин Н. А., Серов В. В., Коган Е. А. и др. Интерстициальные болезни легких - клинические аспекты проблемы. Тер. арх. 1995; 5: 68-71.
  2. Чучалин А. Г. Идиопатический легочный фиброз. Тер. арх. 2000; 3: 5-12.
  3. Попова Е. Н. Идиопатический фиброзирующий альвеолит и интерстициальные пневмонии. Клин. мед. 2005; 6: 21-27.
  4. King T. E., Tooze J. A., Schwartz M. A. et al. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am. J. Respir. Crit. Care Med. 2001; 164 (7): 1161-1181.
  5. Behr J., Ryu J. H. Pulmonary hypertension in interstitial lung disease. Eur. Respir. J. 2008; 31: 1357-1367.
  6. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of The European Society of Cadrioiogy. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. Eur. Heart J. 2004; 25 (24): 2243-2278.
  7. Мартынюк Т. В., Амбатьелло Л. Г., Наконечников С. Н., Чазова И. Е. Диагностика легочной артериальной гипертензии. Тер. арх. 2008; 4: 33-38.
  8. Hall С. The value of natriuretic peptides for the management of heart failure: current state of play. Circulation. 2003; 107 (9): 1278-1283.
  9. McGoon M., Gutterman D., Steen V. et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004; 126 (suppl. 1): 14-34.
  10. Strange C., Highland K. Pulmonary hypertension in interstitial lung disease. Curr. Opin. Pulm. Med. 2005; 11: 452-155.
  11. Елисеев О. М. Натрийуретические пептиды. Эволюция знаний. Тер. apx. 2003; 9: 40-45.
  12. Hall С. NT-ProBNP: the mechanism behind the marker. J. Card. Fail. 2005; 11 (5, suppl.): S81-S83.
  13. Stolz D., Breidthardt Т., Christ-Crain M. et al. Use of B-type natriuretic peptide in the risk stratification of acute exacerbations of COPD. Chest 2008; 133 (5): 1088-1094.
  14. Suntharalingam J., Goldsmith K., Toshner M. et al. Role of NT-proBNP and 6MWD in chronic thromboembolic pulmonary hypertension. Respir. Med. 2007; 101 (11): 2254-2262.
  15. Bando M., Ishii Y., Sugiyama Y. et al. Elevated plasma brain natriuretic peptide levels in chronic respiratory failure with cor pulmonale. Respir. Med. 1999; 93 (7): 507-514.
  16. Allanore Y., Borderie D., Avouac J. et al. High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. Arth. and Rheum. 2008; 58 (1): 284-291.
  17. Simeoni S., Lippi G., Puccetti A. et al. N-terminal pro-BNP in sclerodermic patients on bosentan therapy for PAH. Rheumatol. Int. 2008; 28 (7): 657-660.
  18. Galie N., Olschewski H., Oudiz R. J. et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008; 117 (23): 3010-3019.
  19. Мухин Н. А., Попова Е. Н., Коган Е. А. и др. Клиническое значение ремоделирования легочного сосудистого русла при идиопатическом фиброзирующем альвеолите. Сердеч. недостат. 2007; 8 (4): 178-181.
  20. Мартынюк Т. В., Масенко В. П., Чазова И. Е., Беленков Ю. Н. Эндотелиальная дисфункция у больных с легочной гипертензией. Кардиология 1997; 37 (10): 25-29.
  21. Чазова И. Е., Мартынюк Т. В., Масенко В. П. и др. Роль легких в метаболизме некоторых маркеров повреждения эндотелия в норме и при первичной легочной гипертензии. Кардиология 2000; 40 (8): 13-15.
  22. Emori Т., Hirata Y., Imai Т. et al. Cellular mechanism of natriuretic peptides-induced inhibition of endothelin-1 biosynthesis in rat endothelial cells. Endocrinology 1993; 133 (6): 2474-2480.
  23. Klinger J. R., Warburton R., Carino G. P. et al. Natriuretic peptides differentially attenuate thrombin-induced barrier dysfunction in pulmonary microvascular endothelial cells. Exp. Cell Res. 2006; 312 (4): 401-410.
  24. Mitani Y., Maruyama J., Jiang B. H. et al. Atrial natriuretic peptide gene transfection with a novel envelope vector system ameliorates pulmonary hypertension in rats. J. Thorac. Cardiovasc. Surg. 2008; 136 (1): 142-149.
  25. Makino N., Sugano M., Satoh S. et al. Peroxisome proliferator-activated receptor-gamma ligands attenuate brain natriuretic peptide production and affect remodeling in cardiac fibroblasts in reoxygenation after hypoxia. Cell Biochem. Biophys. 2006; 44 (1): 65-71.
  26. Kim S. Z., Cho K. W., Kim S. H. et al. Modulation of endocardial natriuretic peptide receptors in right ventricular hypertrophy. Am. J. Physiol. 1999; 277 (6, pt 2): H2280-H2289.

Copyright (c) 2009 Mukhin N.A., Fomin V.V., Popova E.N., Kuznetsova A.V., Popova I.A., Churganova L.Y., Osipenko V.I., Mukhin N.A., Fomin V.V., Popova E.N., Kuznetsova A.V., Popova I.A., Churganova L.Y., Osipenko V.I.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail:


© 2018-2021 "Consilium Medicum" Publishing house

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies